Challenges of thyroid cancer management in amiodarone-treated patients: a case report

Thyroid carcinoma (TC) is the most common endocrine malignancy. Although the overall prognosis for patients with TC is good, up to 20–30% of patients have recurrent or persistent disease after conventional therapy by surgical resection and radioactive iodine (RAI). Amiodarone is a highly efficient a...

Descripción completa

Detalles Bibliográficos
Autores principales: PETRULEA, MIRELA SANDA, LENCU, CODRUTA, PICIU, DOINA, LISENCU, COSMIN IOAN, GEORGESCU, CARMEN EMANUELA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iuliu Hatieganu University of Medicine and Pharmacy 2015
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689250/
https://www.ncbi.nlm.nih.gov/pubmed/26733755
http://dx.doi.org/10.15386/cjmed-502
Descripción
Sumario:Thyroid carcinoma (TC) is the most common endocrine malignancy. Although the overall prognosis for patients with TC is good, up to 20–30% of patients have recurrent or persistent disease after conventional therapy by surgical resection and radioactive iodine (RAI). Amiodarone is a highly efficient anti-arrhythmic drug with a very long half-life, so it may interfere with RAI many months after the drug withdrawal. This case report mirrors the challenges of thyroid cancer management in an amiodarone-treated patient.

Ejemplares similares